Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/72130 |
Resumo: | OBJECTIVES: This study aimed to characterize and estimate the frequency of adverse reactions to antituberculosis drugs in the population treated at the Centro de Saúde Escola Germano Sinval Faria, a primary health care clinic in Manguinhos, Rio de Janeiro City, and to explore the relationship between adverse drug reactions and some of the patients' demographic and health characteristics. METHODS: This descriptive study was conducted via patient record review of incident cases between 2004 and 2008. RESULTS: Of the 176 patients studied, 41.5% developed one or more adverse reactions to antituberculosis drugs, totaling 126 occurrences. The rate of adverse reactions to antituberculosis drugs was higher among women, patients aged 50 years or older, those with four or more comorbidities, and those who used five or more drugs. Of the total reactions, 71.4% were mild. The organ systems most affected were as follows: the gastrointestinal tract (29.4%), the skin and appendages (21.4%), and the central and peripheral nervous systems (14.3%). Of the patients who experienced adverse reactions to antituberculosis drugs, 65.8% received no drug treatment for their adverse reactions, and 4.1% had one of the antituberculosis drugs suspended because of adverse reactions. "Probable reactions" (75%) predominated over "possible reactions" (24%). In the study sample, 64.3% of the reactions occurred during the first two months of treatment, and most (92.6%) of the reactions were ascribed to the combination of rifampicin + isoniazid + pyrazinamide (Regimen I). A high dropout rate from tuberculosis treatment (24.4%) was also observed. CONCLUSION: This study suggests a high rate of adverse reactions to antituberculosis drugs. |
id |
USP-19_96c8602ff56430dac8c0f7c6ff05efc7 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/72130 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, BrazilTuberculosisDrug ToxicityPatient Treatment RefusalPrimary Health CareOBJECTIVES: This study aimed to characterize and estimate the frequency of adverse reactions to antituberculosis drugs in the population treated at the Centro de Saúde Escola Germano Sinval Faria, a primary health care clinic in Manguinhos, Rio de Janeiro City, and to explore the relationship between adverse drug reactions and some of the patients' demographic and health characteristics. METHODS: This descriptive study was conducted via patient record review of incident cases between 2004 and 2008. RESULTS: Of the 176 patients studied, 41.5% developed one or more adverse reactions to antituberculosis drugs, totaling 126 occurrences. The rate of adverse reactions to antituberculosis drugs was higher among women, patients aged 50 years or older, those with four or more comorbidities, and those who used five or more drugs. Of the total reactions, 71.4% were mild. The organ systems most affected were as follows: the gastrointestinal tract (29.4%), the skin and appendages (21.4%), and the central and peripheral nervous systems (14.3%). Of the patients who experienced adverse reactions to antituberculosis drugs, 65.8% received no drug treatment for their adverse reactions, and 4.1% had one of the antituberculosis drugs suspended because of adverse reactions. "Probable reactions" (75%) predominated over "possible reactions" (24%). In the study sample, 64.3% of the reactions occurred during the first two months of treatment, and most (92.6%) of the reactions were ascribed to the combination of rifampicin + isoniazid + pyrazinamide (Regimen I). A high dropout rate from tuberculosis treatment (24.4%) was also observed. CONCLUSION: This study suggests a high rate of adverse reactions to antituberculosis drugs.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2013-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/7213010.1590/clin.v68i3.72130Clinics; Vol. 68 No. 3 (2013); 329-337Clinics; v. 68 n. 3 (2013); 329-337Clinics; Vol. 68 Núm. 3 (2013); 329-3371980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/72130/75365Damasceno, Glauciene SantanaGuaraldo, LusieleEngstrom, Elyne MontenegroTheme Filha, Mariza MirandaSouza-Santos, ReinaldoVasconcelos, Ana Gloria GodoiRozenfeld, Suelyinfo:eu-repo/semantics/openAccess2014-01-28T17:05:36Zoai:revistas.usp.br:article/72130Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2014-01-28T17:05:36Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil |
title |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil |
spellingShingle |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil Damasceno, Glauciene Santana Tuberculosis Drug Toxicity Patient Treatment Refusal Primary Health Care |
title_short |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil |
title_full |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil |
title_fullStr |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil |
title_full_unstemmed |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil |
title_sort |
Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil |
author |
Damasceno, Glauciene Santana |
author_facet |
Damasceno, Glauciene Santana Guaraldo, Lusiele Engstrom, Elyne Montenegro Theme Filha, Mariza Miranda Souza-Santos, Reinaldo Vasconcelos, Ana Gloria Godoi Rozenfeld, Suely |
author_role |
author |
author2 |
Guaraldo, Lusiele Engstrom, Elyne Montenegro Theme Filha, Mariza Miranda Souza-Santos, Reinaldo Vasconcelos, Ana Gloria Godoi Rozenfeld, Suely |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Damasceno, Glauciene Santana Guaraldo, Lusiele Engstrom, Elyne Montenegro Theme Filha, Mariza Miranda Souza-Santos, Reinaldo Vasconcelos, Ana Gloria Godoi Rozenfeld, Suely |
dc.subject.por.fl_str_mv |
Tuberculosis Drug Toxicity Patient Treatment Refusal Primary Health Care |
topic |
Tuberculosis Drug Toxicity Patient Treatment Refusal Primary Health Care |
description |
OBJECTIVES: This study aimed to characterize and estimate the frequency of adverse reactions to antituberculosis drugs in the population treated at the Centro de Saúde Escola Germano Sinval Faria, a primary health care clinic in Manguinhos, Rio de Janeiro City, and to explore the relationship between adverse drug reactions and some of the patients' demographic and health characteristics. METHODS: This descriptive study was conducted via patient record review of incident cases between 2004 and 2008. RESULTS: Of the 176 patients studied, 41.5% developed one or more adverse reactions to antituberculosis drugs, totaling 126 occurrences. The rate of adverse reactions to antituberculosis drugs was higher among women, patients aged 50 years or older, those with four or more comorbidities, and those who used five or more drugs. Of the total reactions, 71.4% were mild. The organ systems most affected were as follows: the gastrointestinal tract (29.4%), the skin and appendages (21.4%), and the central and peripheral nervous systems (14.3%). Of the patients who experienced adverse reactions to antituberculosis drugs, 65.8% received no drug treatment for their adverse reactions, and 4.1% had one of the antituberculosis drugs suspended because of adverse reactions. "Probable reactions" (75%) predominated over "possible reactions" (24%). In the study sample, 64.3% of the reactions occurred during the first two months of treatment, and most (92.6%) of the reactions were ascribed to the combination of rifampicin + isoniazid + pyrazinamide (Regimen I). A high dropout rate from tuberculosis treatment (24.4%) was also observed. CONCLUSION: This study suggests a high rate of adverse reactions to antituberculosis drugs. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/72130 10.1590/clin.v68i3.72130 |
url |
https://www.revistas.usp.br/clinics/article/view/72130 |
identifier_str_mv |
10.1590/clin.v68i3.72130 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/72130/75365 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 68 No. 3 (2013); 329-337 Clinics; v. 68 n. 3 (2013); 329-337 Clinics; Vol. 68 Núm. 3 (2013); 329-337 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222759795556352 |